Breast Cancer Evolution During Neoadjuvant Systemic Therapy

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

BELIEVE is a translational research study that aims to collect samples of breast cancer tissue and blood from individuals undergoing breast cancer treatment (such as chemotherapy, targeted therapy and immunotherapy) before surgery. In certain cases, MRI scans and stool samples will also be obtained before and during treatment. The samples collected from this study will be used for molecular and genetic research to understand why some cancers respond very well to anticancer treatments, and some do not, develop novel ways of accurately measuring response during treatment, as well as identify which patients are at a higher risk of the cancer coming back after surgery.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Histologically confirmed non-metastatic invasive breast cancer.

• Be suitable for, but have not commenced, neoadjuvant chemotherapy, targeted therapy, or immunotherapy.

• If HER2-, suitable for treatment with upfront taxane chemotherapy. If HER2+, suitable for treatment with anti-HER2 targeted therapy.

• Be aged 18 years and over.

• Have given written informed consent to participate.

Locations
Other Locations
United Kingdom
Royal Marsden NHS Foundation Trust
RECRUITING
London
Contact Information
Primary
Rebecca Ruiz
BELIEVE@rmh.nhs.uk
02078082887
Backup
Sophie Cooke
sophie.cooke@rmh.nhs.uk
02034373610
Time Frame
Start Date: 2024-05-29
Estimated Completion Date: 2034-05
Participants
Target number of participants: 500
Related Therapeutic Areas
Sponsors
Leads: Royal Marsden NHS Foundation Trust

This content was sourced from clinicaltrials.gov